APA

Parker C., Finkelstein S. E., Michalski J. M., O'Sullivan J. M., Bruland Ø., Vogelzang N. J., Coleman R. E., Nilsson S., Sartor O., Li R., Seger M. A. & Bottomley D. (20180116). Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. : European urology.

Chicago

Parker Christopher, Finkelstein Steven E, Michalski Jeff M, O'Sullivan Joe M, Bruland Øyvind, Vogelzang Nicholas J, Coleman Robert E, Nilsson Sten, Sartor Oliver, Li Rui, Seger Monica A and Bottomley David. 20180116. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. : European urology.

Harvard

Parker C., Finkelstein S. E., Michalski J. M., O'Sullivan J. M., Bruland Ø., Vogelzang N. J., Coleman R. E., Nilsson S., Sartor O., Li R., Seger M. A. and Bottomley D. (20180116). Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. : European urology.

MLA

Parker Christopher, Finkelstein Steven E, Michalski Jeff M, O'Sullivan Joe M, Bruland Øyvind, Vogelzang Nicholas J, Coleman Robert E, Nilsson Sten, Sartor Oliver, Li Rui, Seger Monica A and Bottomley David. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. : European urology. 20180116.